|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-5-21
|
|
pubmed:abstractText |
Tamoxifen, used in breast cancer treatment, competitively inhibits estrogen receptor (ER) and also demonstrates direct antiproliferative effect on cancer cells even in ER lacking cancer tissue. However its molecular mechanism of action is still unclear
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0017-0011
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
81
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
183-7
|
|
pubmed:meshHeading |
pubmed-meshheading:20486538-Antineoplastic Agents, Hormonal,
pubmed-meshheading:20486538-Apoptosis,
pubmed-meshheading:20486538-Cell Division,
pubmed-meshheading:20486538-Cell Line, Tumor,
pubmed-meshheading:20486538-Cisplatin,
pubmed-meshheading:20486538-Drug Interactions,
pubmed-meshheading:20486538-Drug Resistance, Neoplasm,
pubmed-meshheading:20486538-Estrogen Receptor alpha,
pubmed-meshheading:20486538-Estrogen Receptor beta,
pubmed-meshheading:20486538-Female,
pubmed-meshheading:20486538-Humans,
pubmed-meshheading:20486538-Ovarian Neoplasms,
pubmed-meshheading:20486538-Tamoxifen
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Influence of tamoxifen on cisplatin-sensitivity and estrogen receptors expression in ovarian carcinoma cell lines.
|
|
pubmed:affiliation |
Department of Gynaecological Oncology, University of Medical Science, Pozna?, Poland. ewamarkwitz@poczta.fm
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
